<DOC>
	<DOCNO>NCT02306564</DOCNO>
	<brief_summary>The purpose study determine effect give cabergoline patient risk OHSS ( ovarian hyperstimulation syndrome ) ovum pick , endometrial vascularity 's effect pregnancy outcome</brief_summary>
	<brief_title>Effect Cabergoline Endometrial Vascularity During IntraCytoplasmic Sperm Injection</brief_title>
	<detailed_description>Following ethical approval committee obstetrics &amp; gynecology IVF department kasr al-Aini hospital Cairo University , 150 woman attend IVF unit Kasr el Aini hospital management infertility include study obtain informed consent patient . All woman schedule intracytoplasmatic sperm injection ( ICSI ) control ovarian stimulation . All woman include study , apply eligibility criterion , subject careful history take general local examination , follicle stimulate hormone ( FSH ) , luteinizing hormone ( LH ) , Antral follicle count ( AFC ) &amp; Antimullerian hormone ( AMH ) record body mass index ( BMI ) calculation do . BMI define weight kilogram divide height meter square ( kg/m2 ) , Excess weight BMI ≥ 25 kg/m2 obesity BMI ≥ 30 kg/m2 . As patient need cabergoline prevention hyperstimulation obese , therefore BMI ≥ 30 kg/m2 include study . The study include three group , group contain 50 patient . Group A include patient risk OHSS receive Cabergoline 0.5mg daily 8 day ( Dostinex® , Pfizer Australia Pty Ltd ) day oocyte pick prevention hyperstimulation . Group B include patient risk ovarian hyperstimulation syndrome ( OHSS ) receive Cabergoline . While group C serve control group include age &amp; BMI match patient risk OHSS , receive cabergoline . Risk develop ovarian hyperstimulation syndrome ( OHSS ) expectation high oocyte yield include serum E2 &gt; 3,500 pg/ml 20 follicle ≥11 mm day final oocyte maturation , &amp; Patients underwent coast OHSS prevention . The standard long gonadotrophin-releasing hormone ( GnRH ) agonist protocol use patient predict normal response base clinical &amp; hormonal profile ; 1 mg leuprolide acetate daily subcutaneous injection ( s.c ) ( Lucrin ® ; Abbott , Hoofddorp , The Netherlands ) apply mid luteal phase onward till day HCG injection . Gonadotropins form human menopausal gonadotropin ( HMG ) ( Merional ® , IBSA , Institute Biochimique SA , Lugano , Switzerland ) give intramuscular injection ( IM ) 2nd day menstruation confirm regulation ( E2 &lt; 50pg/ml ) , The start dose range 150 300 IU depend basal FSH level , AFC , maternal age BMI . Patients high predict high response evidence high serum AMH ( 4.0 ng/ml ) , invert FSH : LH ratio ( polycystic ovarian syndrome PCOS ) , high antral follicle count ( 30 ) give Antagonist protocol human menopausal gonadotropin ( HMG ) ( Merional ® , IBSA , Institute Biochimique SA , Lugano , Switzerland ) give IM 2nd day menstruation , The start dose range 150 300 IU Gnrh Antagonist cetrorelix acetate ( Cetrotide® , Zentaris IVF GmbH , Australia ) , 0.25 mg S.C , onwards give daily lead follicle reach 14mm . In protocol , stimulation monitor trans-vaginal ultrasonography serial E2 measurement start day 7 cycle gonadotropin dose adjust individually accord follicular response . After development least three lead follicles≥18 mm , 10,000 unit HCG ( Choriomon , IBSA , Institute Biochimique SA ) give IM , trans vaginal ultrasound-guided oocyte retrieval perform 36 hour later . Patients expect high oocyte yield , send last day folliculometry three dimensional ( 3D ) power Doppler determine endometrial vascularity . After ovum pick , Oocytes fertilize vitro use ICSI three five day embryo transfer do use labotec catheter ( Labotec , Gottingen Germany ) ultrasound guidance . A second Trans-vaginal U/S demonstrate endometrial vascularity do 1 hour embryo-transfer . Progesterone pessaries 400 mg twice daily ( Cyclogest 400mg ®Actavis plc . Dublin , Ireland ) give luteal support start day embryo transfer continue 16 day . Pregnancy define occurrence positive beta human chorionic gonadotrophin ( βHCG ) &gt; 10 IU day 12 embryo transfer second high value 2 day later , follow ultrasonography confirmation cardiac activity 6 week gestation . The criterion cycle cancellation : - The presence less three follicle . - E2 level less than500 pg/ml . All 3D ultrasound power Doppler examination carry one investigator day final oocyte maturation repeat day embryo transfer , 1 hour procedure . The Voluson 730 machine ( GE Healthcare Austria GmbH , Seoul , Korea ) endocavitary volumetric 4-9MHz vaginal probe bladder evacuation , Computer-Aided Analysis ( VOCAL™ ) Imaging Program 3D power Doppler histogram analysis use measure endometrial volume ( EV ) 3D power Doppler index within endometrium . Vascularization index ( VI ) measure ratio number color voxels total number voxels ( % ) represent presence blood vessel ( vascularity ) . Flow index ( FI ) measure mean power Doppler signal intensity ( 0−100 ) represent average intensity blood flow . Vascularization flow index ( VFI ) calculate multiply VI FI ( 0−100 ) represent combination vascularity flow intensity</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>1 . Age ≥18 ≤40 year 2 . Normal serum prolactin level . 3 . Tubal factor infertility . 4 . Unexplained infertility . 5 . BMI ≥ 30 kg/m2 . 6 . Estradiol ( E2 ) &gt; 3,500 pg/ml day ovulation trigger . 7 . Patients underwent coast OHSS prevention . 8 . More 20 follicle ≥11 mm day final oocyte maturation . Exclusion criterion : 1 . Contraindication pregnancy e.g . : Somatic mental disease , contraindication carry pregnancy childbirth , inborn malformation acquire deformation uterus cavity make embryo implantation carry pregnancy impossible , ovarian tumor . 2 . Severe Male factor infertility . 3 . Hyperprolactinemic patient . 4 . Frozen embryo transfer cycle 5 . Uterine Anomalies . 6 . Uterine synechia . 7 . History Genital Tuberculosis . 8 . Repeated implantation failure ICSI . 9 . On medication know alter prolactin level e.g antipsychotic , Atypical agent risperidone 10 . Thyroid dysfunction . 11 . Medical disorder affect serum prolactin eg acromegaly , chronic renal failure hypothyroidism</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ICSI</keyword>
	<keyword>cabergoline</keyword>
	<keyword>Subendometrial vascularity</keyword>
</DOC>